CRDL on Nasdaq
Cardiol Therapeutics Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
-33.8MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CAD, the currency the company reports in.
Key numbers, fiscal 2021
Where the money goes
Where each dollar of revenue went, fiscal 2021
- Other costs100¢78.8K CAD
Out of 78.8K CAD in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administration (note 15) | 20.3M CAD | 26.3M CAD |
| Research and development (note 15) | 14.0M CAD | 14.0M CAD |
| Loss before other income (expenses) | -34.3M CAD | -40.3M CAD |
| Interest income (note 6) | 726.4K CAD | 1.2M CAD |
| Gain (loss) on foreign exchange | -1.2M CAD | 2.1M CAD |
| Change in derivative liability (note 9) | 951.7K CAD | 238.2K CAD |
| Other income | 28.2K CAD | |
| Net loss and comprehensive loss for the year | -33.8M CAD | -36.7M CAD |
| Basic net loss per share (in CAD per share) | -0.39 CAD | -0.51 CAD |
| Diluted net loss per share (in CAD per share) | -0.39 CAD | -0.51 CAD |
| Weighted average number of common shares outstanding, basic | 87.0M shares | 71.6M shares |
| Weighted average number of common shares outstanding, diluted | 87.0M shares | 71.6M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents (note 6) | 21.4M CAD | 30.6M CAD | 34.9M CAD |
| Accounts receivable | 55.7K CAD | 100.4K CAD | |
| Other receivables | 170.5K CAD | 261.3K CAD | |
| Prepaid expenses | 1.9M CAD | 726.5K CAD | |
| Total current assets | 23.5M CAD | 31.7M CAD | |
| Property and equipment (note 7) | 118.1K CAD | 195.6K CAD | |
| Total assets | 23.6M CAD | 31.9M CAD | |
| Accounts payable and accrued liabilities | 3.5M CAD | 7.0M CAD | |
| Current portion of lease liability (note 8) | 38.3K CAD | 33.0K CAD | |
| Derivative liability (note 9) | 2.1M CAD | ||
| Total current liabilities | 5.7M CAD | 7.0M CAD | |
| Lease liability (note 8) | 87.2K CAD | 125.5K CAD | |
| Total liabilities | 5.7M CAD | 7.1M CAD | |
| Share capital (note 10) | 201.9M CAD | 179.3M CAD | |
| Contributed surplus | 29.1M CAD | 24.6M CAD | |
| Deficit | -213.1M CAD | -179.3M CAD | |
| Total equity | 17.9M CAD | 24.7M CAD | 28.2M CAD |
| Total equity and liabilities | 23.6M CAD | 31.9M CAD |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss and comprehensive loss for the year | -33.8M CAD | -36.7M CAD |
| Depreciation of property and equipment | 102.0K CAD | 162.8K CAD |
| Amortization of intangible assets | 210.4K CAD | |
| Share-based compensation (note 11) | 10.7M CAD | 14.3M CAD |
| Change in derivative liability | -951.7K CAD | -238.2K CAD |
| Unrealized foreign exchange (gain)/loss on cash | 824.0K CAD | -1.9M CAD |
| Accretion on lease liability | 22.4K CAD | 25.7K CAD |
| Accounts receivable | 44.6K CAD | 42.4K CAD |
| Other receivables | 90.8K CAD | -124.1K CAD |
| Prepaid expenses | -1.1M CAD | 214.9K CAD |
| Accounts payable and accrued liabilities | 263.7K CAD | -1.1M CAD |
| Net cash used in operating activities | -23.9M CAD | -25.1M CAD |
| Purchase of property and equipment | -24.5K CAD | -21.3K CAD |
| Net cash used in investing activities | -24.5K CAD | -21.3K CAD |
| Issuance of units | 16.0M CAD | 21.4M CAD |
| Share issuance costs | -477.0K CAD | -2.7M CAD |
| Proceeds from stock options exercised | 34.3K CAD | 177.5K CAD |
| Payment of lease liability | -55.4K CAD | -41.5K CAD |
| Net cash provided by financing activities | 15.5M CAD | 18.8M CAD |
| Net change in cash and cash equivalents | -8.3M CAD | -6.2M CAD |
| Impact of foreign exchange on cash and cash equivalents | -824.0K CAD | 1.9M CAD |
| Accounts payable and accrued liabilities settled through equity | 3.8M CAD |
Recent filings
- Sep 23, 20266-K
- Sep 23, 2026SCHEDULE 13G/A
- Sep 16, 20266-K
- Sep 16, 2026F-10/A
- Sep 16, 2026SUPPL
- Sep 15, 20266-K
- Sep 11, 20266-K
- Sep 10, 2026F-10
- Sep 10, 2026F-X
- Sep 10, 20266-K
- Sep 9, 20266-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 20266-K
- Aug 5, 20266-K
- Jul 14, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6